S68 of Ph-like acute lymphoblastic leukemia. Blood. Oct 25 2012;120(17):3510-8. doi:10.1182/ blood-2012-03-415448 25. Hurtz C, Wertheim GB, Loftus JP, et al. Oncogeneindependent BCR-like signaling adaptation confers drug resistance in Ph-like ALL. J Clin Invest. Jul 1 2020;130(7):3637-3653. doi:10.1172/JCI134424 26. Tasian SK, Teachey DT, Li Y, et al. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood. Jan 12 2017;129(2):177-187. doi:10.1182/blood-2016-05-707653 27. Sasaki K, Yamauchi T, Semba Y, et al. Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL. Blood. Feb 3 2022;139(5):748-760. doi:10.1182/ blood.2021012976 28. Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. Jun 22 2017;129(25):3322-3331. doi:10.1182/ blood-2017-02-769208 29. Zhao Y, Aldoss I, Qu C, et al. Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood. Jan 28 2021;137(4):471-484. doi:10.1182/blood.2020006287 30. Jabbour E, Roberts KG, Sasaki K, et al. Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Blood. 2019;134:1641. 31. Chang Y, Min J, Jarusiewicz JA, et al. Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia. Blood. Dec 9 2021;138(23):2313-2326. doi:10.1182/blood.2020006846 32. Chang Y, Keramatnia F, Ghate PS, et al. The orally bioavailable GSPT1/2 degrader SJ6986 exhibits in vivo efficacy in acute lymphoblastic leukemia. Blood. May 12 2023;doi:10.1182/blood.2022017813
RkJQdWJsaXNoZXIy MTk3NTQxMg==